A 52-year-old man with type 2 diabetes mellitus and hypertension presents with LDL cholesterol of 180 mg/dL and triglycerides of 320 mg/dL despite lifestyle modifications. His HDL cholesterol is 35 mg/dL. Which is the drug of choice for initial management of his dyslipidemia?

Explanation

## Drug of Choice for Mixed Dyslipidemia with Elevated Triglycerides **Key Point:** In patients with elevated LDL cholesterol AND elevated triglycerides (metabolic syndrome phenotype), statins remain first-line therapy because they reduce LDL-C and have modest triglyceride-lowering effects while providing proven cardiovascular risk reduction. ### Rationale for Atorvastatin Atorvastatin is a potent, high-intensity statin that: - Reduces LDL-C by 40–50% at standard doses - Lowers triglycerides by 20–30% (modest but clinically meaningful) - Increases HDL-C by 5–10% - Has extensive evidence for cardiovascular event reduction in diabetic patients - Is well-tolerated and cost-effective **High-Yield:** In the presence of BOTH elevated LDL and elevated triglycerides, statin monotherapy is preferred over fibrate monotherapy because statins have superior cardiovascular outcome data and address the primary lipid abnormality (LDL-C elevation). ### When to Add Fibrates Fibrates (e.g., fenofibrate) are added as second-line agents if: - Triglycerides remain >200 mg/dL despite statin therapy - Patient has low HDL-C and metabolic syndrome - Risk of pancreatitis from severe hypertriglyceridemia (>500 mg/dL) **Clinical Pearl:** The combination of statin + fibrate increases myositis and rhabdomyolysis risk; monitor CK and renal function closely. ### Comparison of Hyperlipidemic Agents | Agent | Primary Effect | LDL ↓ | TG ↓ | HDL ↑ | First-Line? | |-------|---|---|---|---|---| | **Statin** (Atorvastatin) | LDL-C reduction | 40–50% | 20–30% | 5–10% | **Yes** | | Fibrate (Fenofibrate) | TG reduction | 10–20% | 40–50% | 10–15% | No (2nd-line) | | Ezetimibe | LDL-C reduction | 15–20% | Minimal | Minimal | Adjunct only | | Nicotinic acid | All lipids | 15–25% | 20–30% | 15–25% | Rarely (side effects) | **Warning:** Ezetimibe and nicotinic acid are not first-line monotherapy for this presentation because they lack the robust cardiovascular outcome data of statins and are less effective at LDL reduction.